Allianz SE Acquires New Stake in Edwards Lifesciences Co. (NYSE:EW)

Allianz SE purchased a new position in Edwards Lifesciences Co. (NYSE:EW - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 4,560 shares of the medical research company's stock, valued at approximately $339,000.

A number of other large investors also recently bought and sold shares of EW. Abacus Planning Group Inc. raised its position in shares of Edwards Lifesciences by 0.3% in the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company's stock worth $2,977,000 after purchasing an additional 140 shares during the last quarter. Bowman & Co S.C. raised its holdings in Edwards Lifesciences by 1.2% in the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company's stock worth $924,000 after buying an additional 148 shares during the last quarter. Moors & Cabot Inc. raised its holdings in Edwards Lifesciences by 0.3% in the fourth quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company's stock worth $4,041,000 after buying an additional 152 shares during the last quarter. Pegasus Asset Management Inc. lifted its stake in shares of Edwards Lifesciences by 0.4% in the fourth quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company's stock worth $3,156,000 after buying an additional 159 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC grew its holdings in shares of Edwards Lifesciences by 1.9% during the fourth quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company's stock valued at $634,000 after buying an additional 162 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Edwards Lifesciences Price Performance

Shares of EW traded down $0.71 during mid-day trading on Tuesday, reaching $71.77. The stock had a trading volume of 3,130,437 shares, compared to its average volume of 4,808,167. The business has a fifty day moving average of $71.59 and a 200 day moving average of $70.59. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market cap of $42.19 billion, a price-to-earnings ratio of 10.30, a PEG ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Equities analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In related news, CEO Bernard J. Zovighian sold 6,164 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $69.51, for a total value of $428,459.64. Following the completion of the transaction, the chief executive officer now owns 59,083 shares of the company's stock, valued at approximately $4,106,859.33. This trade represents a 9.45 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total value of $797,287.50. Following the completion of the transaction, the chief financial officer now owns 30,387 shares of the company's stock, valued at approximately $2,153,526.69. This trade represents a 27.02 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 62,553 shares of company stock worth $4,513,064. Insiders own 1.29% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on EW shares. Wolfe Research lowered shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $85.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Canaccord Genuity Group increased their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research report on Thursday, February 13th. The Goldman Sachs Group boosted their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a "buy" rating in a research report on Thursday, December 5th. Finally, Stifel Nicolaus raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and raised their price target for the company from $75.00 to $90.00 in a report on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.